C
Circulate
Health Tech & Medtech · Seattle, United States · Founded 2021
FDA-cleared Therapeutic Plasma Exchange (TPE) for anti-aging, delivered through a growing network of independent medical clinics in the US MoreLess
Circulate Health is focused on the anti-aging and wellness market by providing Therapeutic Plasma Exchange (TPE) treatments. The company's core offering is built upon proprietary, FDA-cleared apheresis technology, which is supported by two decades of scientific research and clinical trials.
The business operates on a partnership model, expanding its services through a network of independent medical practices and clinics. Currently, TPE by Circulate is available in over 21 clinics across the United States, with a clear strategy for continued growth. This model allows the company to scale its reach by equipping partner clinics to deliver the treatments.
Circulate targets two primary client segments: patients seeking treatments to improve their quality of life and healthy lifespan, and medical clinics or doctor's offices looking to offer these services. The company's revenue is likely generated through the provision of its TPE technology and services to its partner clinics, which in turn serve the end patients. Clinical services are delivered by these independent practices, with Circulate providing the foundational technology and scientific backing.
Keywords: Therapeutic Plasma Exchange, TPE, anti-aging, longevity, apheresis, FDA cleared, medical clinics, wellness, plasma exchange, lifespan
Company overview
Circulate company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2021
- Headquarters
- Seattle, United States
- Employees
- 23
- Open positions
- 1
- Dealroom signal
- 87.5
Valuation & funding
Circulate funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2026 | $0 | — | Viome | ↗ |
| EARLY VC✓Equity / VC | Dec 2025 | $0 | — | Scrum Ventures | ↗ |
| SEED✓Equity / VC | Jun 2025 | $12M | $48M | Khosla Ventures | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 23 |
| 2025 | 14 |
Growth signals
Circulate website traffic
Latest recorded traffic for Circulate is 2K monthly website visits, down 4.8% over the last three months. Circulate's team grew 64.3% over the past year.
Hiring
Open positions at Circulate
Current openings linked to this company in Dealroom.
Comparisons
Circulate compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Circulate's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Circulate has talent and traffic
team presence
In the news
Latest news about Circulate
Recent press, funding announcements, and product moves mentioning Circulate — open to read from the original sources.
Market sentiment
What the market is saying about Circulate
An AI-synthesized read of the highest-engagement posts about Circulate on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Circulate’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.